drugset / Trial / NCT03219437

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

NCT03219437

Phase 3 Completed 104 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.

Timeline

Start
2018-07-30
Primary completion
2021-11-26
Completion
2021-11-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methotrexate Small molecule
Subject Risankizumab Monoclonal antibody Subcutaneous

Indications